Company: CYTK
Filing Date: 2025-09-22
Form Type: 8-K
Source: 0001193125-25-209437
Chunk: 8

Company: CYTOKINETICS INC
Filing Date: 2025-09-22
Form: 8-K
Item: Item 9.01
Chunk 8
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit Number      Description                                                                                                                                      
             4.1      Indenture, dated as of September 19, 2025, between Cytokinetics, Incorporated and U. S. Bank Trust Company, National Association, as trustee.    
            99.1      Press Release issued by the Company on September 16, 2025.                                                                                       
            99.2      Press Release issued by the Company on September 16, 2025.                                                                                       
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
             4.2      Form of Note, representing the Company’s 1.75% Convertible Senior Notes due 2031 (included as Exhibit A to the Indenture filed as Exhibit 4.1).  
             104      Cover page interactive data file (embedded within the inline XBRL document).                                                                     

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                CYTOKINETICS, INCORPORATED                                                         
  Date: September 19, 2025      By:                             /s/ Sung H. Lee                                    
                                                                Sung H. Lee                                        
                                                                Executive Vice President, Chief Financial Officer